Influenza Workgroup

Introduction

Ruth Karron, MD

Advisory Committee on Immunization Practices
October 24, 2013

Influenza Work Group

ACIP Members

Ruth Karron (Chair)
Jeff Duchin
Lee Harrison

Ex Officio Members

Melisse Baylor (FDA)

David Cho (FDA)

Jesse Geibe (DoD)

Bruce Gellin (HHS)

Lucia Lee (FDA)

Cynthia Noletti (FDA)

Rachelle Salomon (NIH)

CDC Lead

Lisa Grohskopf (CDC/OID/NCIRD, Influenza Division)

Liaison Representatives

Kevin Ault (ACOG)

Hank Bernstein (AAP)

Jan Englund (PIDS)

Sandra Fryhofer (ACP; AMA)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Jamie Loehr (AAFP)

Kathy Neuzil (IDSA)

Lisa Ipp (SAHM)

William Schaffner (NFID)

Rob Schechter (AIM)

Ken Schmader (AGS)

Nadine Sicard (NACI)

Patsy Stinchfield (NAPNAP)

Tamara Sheffield (AHIP)

Matthew Zahn (NACCHO)

Developments Since June ACIP

- Publication of 2013-14 ACIP Influenza Statement
 - Virus strains selected for 2013-2014 vaccine
 - Summary of 6 recently approved vaccines
 - Revision of egg allergy statement to include Flublok for 18-49 yrs
- □ Licensure of FLULAVAL® Quadrivalent (GSK)
 - Inactivated quadrivalent influenza vaccine (IIV4) for persons aged 3 and older.
- New age indication for FLULAVAL® Trivalent (GSK)
 - Now licensed for persons aged 3 & older (previously 18 & older)
- Discussion of Fluzone® High-Dose vaccine

Agenda Overview

- Influenza Surveillance Update
 - Lisa Grohskopf (CDC—Influenza Division)
- Influenza Vaccine Distribution and Coverage, 2012-2013 Season
 - James Singleton (CDC—Immunization Services Division)
- □ Fluzone High-dose Vaccine Efficacy Trial Results
 - David Greenberg (Sanofi Pasteur)